Endocrine Abstracts

Introduction: Diabetes mellitus (DM) increases the risk of any form of cardiovascular (CVD) and renal disease. Their identification is important for a further careful monitoring and treatment in all aspects. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been associated with a remarkable reduction of cardiovascular and renal mortality, lower hospitalization rates for heart failure and lower progression of renal damage and albuminuria. Our study aim to assess SGLT2i effects on both cardio- and renal protection in diabetic patients.

Material and Methods: Were included elderly patients (>65 years) with T2DM, divided in two groups, one group treated with iSGLT2, and the other without. Data were collected at the beginning of treatment, 3, 6, 9 and 12 months after. HbA1C, BMI, GFR and renal parameters, uric acid, NTproBNP, echocardiography, PAS and PAD values, were evaluated in every meetings, in both groups.

Results: Included in total 298 elderly diabetic patients. At 198 of them dapagliflozin 10 mg, was initiated. After 12 months, HbA1c, weight, systolic blood pressure, NTproBNP, uric acid, albuminuria, were lower in group with dapagliflozin versus the other group without it, and estimated glomerular filtration rate was higher (75.3 –87.19mL/min/1.73m²; P<0.005). Follow up in patients with SGLT2i showed a significant decrease in left ventricular end-diastolic dimension (LV-EDD) (62.86 mm to 54.85 mm; P<0.001) and improvement in LV-EF. The SGLT2i-induced improvements in cardiac function were more prominent in HF patients than those without HF.

Conclusion: SGLT2i (Dapagliflozin) showed metabolic benefits in patients with T2D with clinically significant reductions in HbA1c, blood pressure, weight, uric acid, and NTproBNP. Cardiovascular and renal benefits were shown, also. So, SGLT2i has a significant effect in both, cardio- and renal protection in diabetic patients.